1. Home
  2. SFWL vs KLRS Comparison

SFWL vs KLRS Comparison

Compare SFWL & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shengfeng Development Limited

SFWL

Shengfeng Development Limited

N/A

Current Price

$5.10

Market Cap

46.5M

Sector

Industrials

ML Signal

N/A

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

HOLD

Current Price

$1.55

Market Cap

44.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SFWL
KLRS
Founded
2001
2019
Country
China
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
46.5M
44.5M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
SFWL
KLRS
Price
$5.10
$1.55
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $16.33
AVG Volume (30 Days)
16.5K
★ 74.2K
Earning Date
09-15-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 75.70
EPS
★ N/A
N/A
Revenue
N/A
★ $165,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.06
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$1.41
52 Week High
$12.00
$11.88

Technical Indicators

Market Signals
Indicator
SFWL
KLRS
Relative Strength Index (RSI) 45.31 30.35
Support Level $0.80 N/A
Resistance Level $9.94 $2.66
Average True Range (ATR) 0.77 0.23
MACD -0.01 -0.03
Stochastic Oscillator 52.65 12.03

Price Performance

Historical Comparison
SFWL
KLRS

About SFWL Shengfeng Development Limited

Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services. The company's operations are based in the PRC. Its integrated logistics solutions are comprised of three business streams: B2B freight transportation services; cloud storage services; and value-added services. The company derives maximum revenue from Transportation, followed by Warehouse storage management services. The solutions provides by the company are : Internet TV; Electronic communication; Textiles and Apparel; Automotive parts; and e-commerce.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: